iCo Therapeutics Announces Major Milestone - Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has dosed the first patient in its Phase 1 clinical study for Oral Amphotericin B. "Dosing our first patient is a major milestone for iCo Therapeutics and the oral Amphotericin B program" stated Andrew Rae, President and CEO of iCo Therapeutics Inc. "We currently remain on...
2018-04-18 8:00 AM EDT
iCo Therapeutics Announces Third Quarter 2017 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended September 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the quarter, we continued to advance our novel Oral Amphotericin B (Oral Amp B) candidate towards the clinic, and we are pleased...
2017-11-28 5:00 PM EST
IIROC Trade Resumption - iCo Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - Trading resumes in: Company: iCo Therapeutics Inc.
2017-11-22 1:33 PM EST
iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its recently formed subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has been granted ethics approval in Australia to conduct its proposed Phase 1 clinical study for Oral Amphotericin B. Amphotericin B is a well-known approved drug for the treatment of fungal and parasitic infections but the therapy is currently limited by...
2017-11-22 1:20 PM EST
IIROC Trade Halt - iCo Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - The following issues have been halted by IIROC: Company:
2017-11-22 8:59 AM EST
iCo Therapeutics Announces Upcoming Presentations and Meetings
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced that it has been invited to present at the following upcoming conferences:19th Annual Rodman and Renshaw Global Investment Conference, New York, New YorkiCo is currently scheduled to present at the 19th Annual Rodman and Renshaw Global Investment Conference being held between September 10th and 12th, 2017 at the Lotte New York Palace Hotel,...
2017-09-07 7:11 PM EDT
iCo Therapeutics Announces Second Quarter 2017 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - August 29, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended June 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the quarter, we reported the results of our preclinical, 14-day, GLP toxicology study with our novel Oral Amphotericin B (Oral Amp B)...
2017-08-29 5:00 PM EDT
iCo Therapeutics Inc. Approves Advance Notice Policy
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced that its board of directors has adopted an advance notice policy (the "Advance Notice Policy").The purpose of the Advance Notice Policy is to provide shareholders, directors and management of the Company with direction on the procedure for shareholder nomination of directors. The Advance Notice Policy is the framework by which the Company...
2017-08-05 2:00 AM EDT
iCo Therapeutics Announces Election of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the election of directors at the annual meeting of shareholders held on June 29, 2017. At the annual meeting of shareholders held on June 29, 2017, Andrew Rae, Susan Koppy, Wiiliam Jarosz and Michael Liggett were elected directors of the Company and will hold office until the next annual general meeting of shareholders. About iCo...
2017-06-30 7:13 PM EDT
iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017. Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a pre-clinical proof...
2017-06-15 4:15 PM EDT
iCo Therapeutics Announces Positive Oral Amphotericin Study
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported the successful conclusion of pre-clinical studies involving its lead oral Amphotericin B candidate, including compelling safety data from its pivotal 14 day GLP (Good Laboratory Practices compliant) toxicology study.Data from its IND enabling 14 day GLP study conducted in Toronto, Ontario facilities revealed that oral administration of...
2017-06-12 8:00 AM EDT
iCo Therapeutics Announces First Quarter 2017 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the first quarter, we substantially completed our preclinical, 14-day, GLP toxicology study with our novel Oral Amphotericin B (Oral Amp B)...
2017-05-24 6:08 PM EDT
iCo Therapeutics Announces Year End 2016 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - April 19, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the year ended December 31, 2016. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").2016 Financial & Operational HighlightsWe continued to advance our Oral Amphotericin B Delivery System (Oral Amp B), undertaking pre-clinical...
2017-04-19 8:38 PM EDT
iCo Therapeutics Inc. Announces No Material Change
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") reports that at the request of IIROC, the Company wishes to confirm that management is unaware of any material change in their operations that would account for the recent increase in market activity.About iCo Therapeutics iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may...
2017-03-13 2:43 PM EDT
iCo Therapeutics Provides Multiple Corporate Updates
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announces several corporate developments.Regarding our Oral Amphotericin B program, multiple, additional pre-clinical studies have been initiated including a multi-day fasted/fed study, a 7-day dose range finding study and, importantly, a 14 day GLP toxicology study. iCo expects all three studies to be substantially complete during Q1 2017. Together these...
2017-01-23 8:00 AM EST
IIROC Trade Resumption - iCo Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2016) - Trading resumes in: Company: iCo Therapeutics Inc.
2016-11-28 12:21 PM EST
CLARIFICATION: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2016) - Vancouver, British Columbia--(Newsfile Corp. - November 28, 2016) - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company"), announces several developments related to its novel, patent protected formulation of generic Amphotericin B:Positive Oral Amphotericin B (Oral Amp B) study results exhibited pharmacokinetic (PK) and tissue accumulation data with clinical and commercial relevance:demonstrating scalable and...
2016-11-28 11:53 AM EST
IIROC Trade Halt - iCo Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2016) - The following issues have been halted by IIROC: Company:
2016-11-28 9:30 AM EST
iCo Therapeutics Announces Positive Study Results and Significant Advances Related to Oral Amphotericin B Program
Vancouver, British Columbia--(Newsfile Corp. - November 28, 2016) - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company") announces several developments related to its novel, patent protected formulation of generic Amphotericin B:-Positive Oral Amphotericin B (Oral Amp B) study results exhibited pharmacokinetic (PK) and tissue accumulation data with clinical and commercial relevance:-demonstrating scalable and stable drug product, now at a higher dose form -once daily regime...
2016-11-28 8:00 AM EST
iCo Therapeutics Announces Third Quarter 2016 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - November 24, 2016) - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended September 30, 2016. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the third quarter, we initiated a preclinical pharmacokinetic and distribution study with our novel Oral Amphotericin B (Oral Amp B)...
2016-11-24 8:00 AM EST